NTRA
Natera Inc
$363.76-6.97%
Setup
No setup
Buy Zone
$358.03-$375.93
Sector
Diagnostics & Research
Industry
Diagnostics & Research
70
Recommendation
No setup
Hold
No active chart path confirmed. Keep on watchlist until price, volume, and setup align.
NTRA chart
Loading chart…
Overall Quality70
RS Rating
94
relative strength
Fundamentals
50
Weak fund-Q
Volume Demand
68
+100% vs avg
Technical Setup
38
3/8 checks
Industry/Theme
91
Diagnostics & Research
Trade Plan
No setup
Entry
$358.03
Entry Zone
$358.03-$375.93
Stop / Risk
$329.39
RS Rating
94
Volume confirmed
No
Targets
$429.64 / $447.54
Breakout · IBD Setup
3 ✓ 5 ✗
Entry $358.03–$375.93Stop $329.39Target $429.64 / $447.54
Market regimeRange
Quality70
RS Rating94
Above 50-MA-4.48%
Above 200-MA+35.22%
VolumeWeak
In Buy ZoneNo
Not extendedOK
Invalidation · Close below stop
How this came together
70
MarketRange
SetupNo setup
ConfidenceExperimental · not backtested
Fund-Q50 · Weak
StatusHold
Stock Data
52-Week Range181 – 437
Price % Chg YTD58.78%
Price % Chg 4wk-8.04%
50-Day Avg Vol1.6 Mil
P/E Ratio—
Market Cap$60B
SectorHealthcare
IndustryDiagnostics & Research
Company Fundamentals
EPS % Chg (Qtr)36.85%
Sales % Chg (Qtr)37.71%
EPS Growth 5y11.7%
Sales Growth 5y42.61%
Annual ROE-12.54%
Gross Margin64.74%
Operating Margin-10.56%
Net Margin-7.11%
Debt / Equity0.13
Setup levels
Current price
$363.76
Pivot
$358.03
Distance to buy
-16.8%
52-week range
181-437.42
Trigger evidence
No active trigger evidence available.
Financial health checks
3/5
Return on equity above 15%
ROE -12.54%
Net margin above 10%
Net margin -7.11%
EPS growing quarter on quarter
EPS q/q 36.85%
Sales growing quarter on quarter
Sales q/q 37.71%
Debt to equity below 1.0
D/E 0.13
Key metrics
Finviz snapshot · value vs. sector median (≥5 peers)
Annual ROE-12.54%
vs sector -35.1%
Net margin-7.11%
vs sector -24.8%
Gross margin64.74%
vs sector -2.4%
EPS growth q/q36.85%
vs sector +29.3%
Sales growth q/q37.71%
vs sector +19.0%
Debt / equity0.13
vs sector -0.52
Business quality
50
GradeWeak
EPS rating60
P/E—
Market cap$60B
IndustryDiagnostics & Research
Technical checks
Über 50-MA
Fail
Über 200-MA
Pass
RS-Linie auf neuem Hoch
Fail
Volumen bestätigt
Fail
In Kaufzone
Fail
Nicht überextended
Pass
Über 21-EMA
Fail
Volumen gesund
Pass
IBD / source mentions
No recent IBD mention found for this ticker.
Signal history
Added to list
2026-10-29
Trigger date
—
Days on list
8
Data sources: internal CANSLIM engine · Finviz snapshot · TradingView chart. Not investment advice.